Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARNA Arena Pharmaceuticals	$99.99	$97.65	$45.50 ▼ $100.00	$6.17B	0.55	1.56 million shs	107 shs
CCXI ChemoCentryx	$51.99	$51.95	$14.95 ▼ $52.00	$3.71B	1.22	1.68 million shs	113 shs
FTSV Forty Seven	$95.51	$95.51	$5.53 ▼ $95.51	$4.60B	0.4	1.61 million shs	N/A
INSM Insmed	$131.88 -0.5%	$106.82	$60.40 ▼ $133.56	$27.88B	0.95	2.82 million shs	2.10 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARNA Arena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CCXI ChemoCentryx	0.00%	0.00%	0.00%	0.00%	0.00%
FTSV Forty Seven	0.00%	0.00%	0.00%	0.00%	0.00%
INSM Insmed	+2.43%	+3.80%	+28.84%	+96.36%	+72.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CCXI ChemoCentryx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INSM Insmed	4.028 of 5 stars	2.5	4.0	0.0	4.3	3.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARNA Arena Pharmaceuticals	0.00	N/A	N/A	N/A
CCXI ChemoCentryx	0.00	N/A	N/A	N/A
FTSV Forty Seven	0.00	N/A	N/A	N/A
INSM Insmed	2.94	Moderate Buy	$132.57	0.52% Upside

Current Analyst Ratings Breakdown

Latest INSM, ARNA, FTSV, and CCXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$126.00 ➝ $144.00
8/20/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$111.00 ➝ $135.00
8/20/2025	INSM Insmed	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/14/2025	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$126.00 ➝ $139.00
8/14/2025	INSM Insmed	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$121.00 ➝ $145.00
8/13/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$114.00 ➝ $142.00
8/13/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$126.00
8/13/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$129.00 ➝ $148.00
8/13/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $165.00
8/12/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $140.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARNA Arena Pharmaceuticals	$50K	123,305.67	N/A	N/A	$10.94 per share	9.14
CCXI ChemoCentryx	$32.22M	115.14	N/A	N/A	$4.09 per share	12.71
FTSV Forty Seven	$15.68M	293.33	N/A	N/A	$7.52 per share	12.70
INSM Insmed	$363.71M	76.65	N/A	N/A	$5.91 per share	22.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARNA Arena Pharmaceuticals	-$616.43M	-$10.13	N/A	N/A	N/A	N/A	-69.83%	-62.35%	N/A
CCXI ChemoCentryx	-$131.76M	-$1.89	N/A	N/A	N/A	-357.01%	-48.52%	-30.59%	N/A
FTSV Forty Seven	-$87.62M	-$2.34	N/A	N/A	N/A	N/A	-50.38%	-44.35%	N/A
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)

Latest INSM, ARNA, FTSV, and CCXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CCXI ChemoCentryx	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARNA Arena Pharmaceuticals	0.05	8.59	8.59
CCXI ChemoCentryx	0.02	4.54	4.47
FTSV Forty Seven	N/A	14.81	14.81
INSM Insmed	0.45	6.68	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARNA Arena Pharmaceuticals	83.77%
CCXI ChemoCentryx	81.09%
FTSV Forty Seven	71.77%
INSM Insmed	N/A

Insider Ownership

Company	Insider Ownership
ARNA Arena Pharmaceuticals	2.41%
CCXI ChemoCentryx	8.30%
FTSV Forty Seven	37.40%
INSM Insmed	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARNA Arena Pharmaceuticals	448	61.66 million	60.17 million	Optionable
CCXI ChemoCentryx	178	71.36 million	65.43 million	Optionable
FTSV Forty Seven	57	48.16 million	N/A	Not Optionable
INSM Insmed	1,271	211.38 million	205.03 million	Optionable

INSM, ARNA, FTSV, and CCXI Headlines

Recent News About These Companies

Insmed (NASDAQ:INSM) Price Target Raised to $135.00

August 22 at 11:11 AM | marketbeat.com

Insmed (NASDAQ:INSM) Now Covered by Analysts at William Blair

August 22 at 9:16 AM | marketbeat.com

Insmed (NASDAQ:INSM) Director Melvin Md Sharoky Sells 10,000 Shares

August 22 at 7:53 AM | insidertrades.com

Algert Global LLC Trims Stock Position in Insmed, Inc. $INSM

August 22 at 4:44 AM | marketbeat.com

State of New Jersey Common Pension Fund D Cuts Stock Position in Insmed, Inc. $INSM

August 22 at 4:27 AM | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

August 22 at 3:27 AM | americanbankingnews.com

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

August 21 at 11:53 AM | benzinga.com

Insmed price target raised to $144 from $126 at Morgan Stanley

August 21 at 11:53 AM | msn.com

Insmed (NASDAQ:INSM) CEO Sells $881,466.00 in Stock

August 21 at 7:45 AM | insidertrades.com

Insmed To Present at September Investor Conferences

August 21 at 7:00 AM | prnewswire.com

William Blair Initiates Coverage of Insmed (INSM) with Outperform Recommendation

August 21 at 6:53 AM | msn.com

American Century Companies Inc. Buys 59,343 Shares of Insmed, Inc. $INSM

August 21 at 4:26 AM | marketbeat.com

Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 21 at 2:54 AM | marketbeat.com

Insmed price target raised to $135 from $111 at JPMorgan

August 20 at 4:07 PM | msn.com

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

August 20 at 2:46 PM | benzinga.com

Insmed (NASDAQ:INSM) Sets New 1-Year High - Here's Why

August 20 at 11:47 AM | marketbeat.com

Aberdeen Group plc Grows Position in Insmed, Inc. $INSM

August 20 at 5:20 AM | marketbeat.com

Insmed, Inc. (NASDAQ:INSM) Given Average Rating of "Moderate Buy" by Brokerages

August 20 at 2:55 AM | americanbankingnews.com

Josh Brown's Best Stocks in the Market: Insmed

August 19 at 2:12 PM | youtube.comY

Rep. Gilbert Ray Cisneros, Jr. Sells Insmed, Inc. (NASDAQ:INSM) Shares

August 19 at 5:00 AM | marketbeat.com

Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market

August 18, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM, ARNA, FTSV, and CCXI Company Descriptions

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Forty Seven NASDAQ:FTSV

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Insmed NASDAQ:INSM

$131.88 -0.72 (-0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$131.76 -0.13 (-0.09%)

As of 07:15 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time